Endodiag

Founded 2011
Employees 10+
Primary contact
Pépinière Paris Santé Cochin
29 rue du Faubourg Saint Jacques
75014 Paris
France
Endodiag is specialized in the development of products and services aimed at improving the diagnosis of endometriosis, a complex and poorly known disease. With its EndoGram prognosis program, Endodiag contributes to improving current diagnostic practice by providing additional biological information for personalized medical and therapeutic management for each patient. In parallel, the company develops a new non-invasive diagnostic test (EndoDTect), making endometriosis detection much easier and faster. Finally, Endodiag offers drug testing services to pharmaceutical companies enabling them to make the early in-vitro evaluation of drug efficacy of cell lines and patient-derived cell cultures.
Founded 2011
Employees 10+
Primary contact
Pépinière Paris Santé Cochin
29 rue du Faubourg Saint Jacques
75014 Paris
France

Funding 💰

Total $9.1M
Select investors Karista, Medevice, CM-CIC, BNP Paribas Développement

Key people 🧑‍🤝‍🧑

Highlights

  • Solving a problem: Although endometriosis is a major cause of subfertility (40% of affected patients are infertile) and chronic pain, it takes an average of 8 to 10 years between the onset of the disease and its diagnosis, currently only achieved through surgery.
  • Riding the wave: Endodiag is part of the global femtech industry, which is expected to grow at a CAGR of 13% from 2021 to 2026.
  • Big addressable market: Endometriosis affects 10% of women of reproductive age or over 180 million patients worldwide.
  • Scientific co-founders: The company leverages the experience of its scientific cofounders who have been working in this field for over 20 years.

Video ▶️

Awards & Recognitions 🏆

  • 2020 Galien Medstartup: Nominee 🔗
  • 2016 France Biotech: Trophée de l'entrepreneur en santé femme 🔗
  • 2012 Cartier Women's Initiative Awards: Finalist 🔗
Last update: January 13, 2023